Assessment of *Helicobacter pylori* positive infected patients according to Clarithromycin resistant 23S rRNA, *rpl22* associated mutations and *cyp2c19* *1, 2, 3* genes pattern in the Early stage of Gastritis

Atena Abedi Maghami1, Ashraf Mohabati Mobarez1*, Abbas Yadegar2, Maryam Nikkhah3, Amir Sadeghi4 and Saber Esmaeili5

**Abstract**

**Objective:** Clarithromycin resistant *Helicobacter pylori* (CAM-R) is the main cause of standard triple therapy eradicating failure. Proton pump inhibitors (PPIs) directly pose bacteriocidic activity and prepare the optimum condition for Clarithromycin’s best function. In counter with Poor metabolizer subjects, Homozygote Extensive Metabolizers have well characterized by treatment failure. Eventually, determination of CAM-R profile and estimation of PPIs metabolism rate support clinicians in better prescription. So, we explored *Helicobacter pylori* mutations in 23S rRNA and *rpl22* resistant genes, and *cyp2c19* *1, 2, 3* allele variations, and PPIs metabolism patterns in patients, consequently the results reported to the physician.

**Results:** Sixteen out of 96 patients considered to be CAM-R *Helicobacter pylori*. A2143C (1/16), *rpl22* insertion (16/16), and GTG deletion (2/16) recorded in CAM-R strains. P450 2C19 human genotyping demonstrated that the highest proportion of the *H. pylori*-positive strains infected patients 43/61 (70.49%) categorized in Homozygote extensive metabolizer class. The rest (12/61) 19.67% classified as Poor metabolizers, and 6/61 (9.83%) distinct from Heterozygote extensive metabolizer group. Proportion of poor metabolizers and Heterozygote extensive metabolizer phenotypes between CAM-R strains mentioned to be 10/16 (62.5%), and 6/16 (37.5%). Cross points between the most frequently distributed allele in CAM-R strains indicated 81.25% for *2*, and *w2* for 18.75%.

**Keywords:** Clarithromycin resistant, *Helicobacter pylori*, Homozygote extensive metabolizer, Heterozygote extensive metabolizer, Poor metabolizer

**Introduction**

Lower efficient *Helicobacter pylori* eradication by standard triple therapy (STT) has been directly related to the incensement of Clarithromycin resistance rate (CAM-R) [1]. Nevertheless, many compensatory mutations, 23S rRNA related-point mutations A2142G/C, A2143G/C, and recently *rpl22* polymorphisms (GTG deletion and
TTCCATGTA insertion) are individually discussed among CAM-R strains [2–4].

Proton pump inhibitors (PPIs) covalently interact with the cysteine residue of proton pumps which inhibit H+ releases, thereby collaboration of PPIs in prescription promotes stability and concentration of Clarithromycin. P450 CYP 2c19 is the liver catabolic enzyme that dominantly corresponds to the metabolism of omeprazole and lansoprazole [5–7]. Among 34 cyp2c19 allele polymorphisms distinct for the deficiency in drug metabolism, there are three major losses of functions (LOF) cyp2c19*2 (681 G ≥ A), cyp2c19*3(636 G ≥ A), and cyp2c19*17 (806 C ≥ T) in which cyp2c19*2 and cyp2c19*3 are mainly reputed in Asian population than cyp2c19*17 for less than 1% [7].

Based on the cyp2c19 variants, subjects have been categorized into three groups: Homozygote extensive metabolizer (Hom-EM) with two wild types of allelic polymorphism, Heterozygote extensive metabolizer (Het-EM) with LOF *2 or *3, and poor metabolizer (PM) with two losses of function *2 and *3 [8]. Furuta was the pioneer in the evaluation of cyp2c19 human genotyping and prediction of cure rate after treatment regime consumption. Beyond the series of randomized clinical trial studies, the eradication rate in the PM group that took the standard dosage of PPIs was considered to be high and in EM participants were reported to be very low, so the presumption of the infection recurrence comes to be high [9, 10].

Thus, to support clinicians in better scheduling, and prevention of drug resistance increase we performed PCR amplification, and sequencing to evaluate CAM-R related point mutations in 23S rRNA and rpl22 genes, and Realtime-PCR in the classification of total patients in the early stage of gastritis in Helicobacter pylori positive infected individuals, and Clarithromycin resistant strains infected patients based on cyp2c19 gene mapping.

Main text

Material and methods

Total of 96 consenting participants were concluded in this associational study, during the period of April 5th, 2020 to October 9th, 2020. H. pylori phenotypically and molecular characterization, bacterial phenotypically antimicrobial drug resistance (ADR), subsequently 23S rRNA and rpl22 polymorphisms confer CAM-R, determined by PCR amplification, and sequencing that subscribed in Additional files 1 [11, 12] and 2. To detect cyp2c19 *1, *2 and *3 LOF primers designing were clarified in Additional file 3. Reagents preparation and RT-PCR performance in the differentiation of total patients, H. pylori-positive subjects, CAM-R strains infected one according to, cyp2c19 mentioned variants described in Additional file 4. Additional file 5 (Table S5) have contented cyp2c19 *1, *2, *3, 23S rRNA, and rpl22 pair primers list.

Statistics analysis

The SPSS Statistics for Windows (version 21.0, IBM Corp, Armonk, NY, USA) and Chi-Square (χ2) Definition were applied to search for associations between the variables and classification of the population studied; p ≤ 0.05 was considered to be significant range in interpretation.

Results

Describes the characteristic of the patients from whom H. pylori strains were isolated by histopathology test, molecular identification, and bacterial culturing illustrated in Additional file 6. Additional file 7 illustrate the image of early stage of gastritis.

Cyp2c19*1, *2, and *3 allele distribution

According to our experimental study, frequent allelic polymorphism in the total number of enrolled patients between cyp2c19 *1(which is the wild type) *2 and *3, denoted for *3 (81.25%), p ≤ 0.001. The next were *2 for (13.5%) p-value ≤ 0.001, *2(3.125%) p ≤ 0.75 and *3(2.08%) p ≤ 0.75.

According to the present study, the frequency of *3 and *2 in distribution were the lowest but more than 1%. Chi-Square (χ2) Statistic analysis reports of cyp2c19 *1 variant distributed in the total patients attended in this work (as the reference group) in comparison to histopathological positive Helicobacter pylori, molecular positive H. pylori, and culture positive group considered to be significant p ≤ 0.001, and in CAM-R strains reported for p = 0.75. cyp2c19 *2 allele-span through mentioned classified groups considered to be significant p ≤ 0.001 and circulation of cyp2c19 *3 within total examined subjects noted for p ≤ 0.75.

Accumulation of cyp2c19 *2 variants among phenotypically and molecular characterized CAM-R strains

Distribution of the cyp2c19 *1, *2, and *3 allelic polymorphism inter culture positive Helicobacter pylori strains demonstrated the prevalence of *2(37.14%) and *2(8.57%) and *3(3.71%), totally. The dominant allelic-polymorphism through CAM-resistant strains 81.25% was recorded for *2 p ≤ 0.001, and 18.75% for *2 p ≤ 0.75, respectively. Because of the accumulation of rpl22 9 bp insertion, rpl22 3 bp deletion, and the only one A2143C point mutation related to CAM-resistance in *2 PM, and *2 Het-EM metabolizer class; therefore, it is clear that the cross point between the most frequent allele that distributed in CAM-R strains will be
*2 (81.25%), and *2 for 18.75%. The distribution of *3 and *3 among CAM-resistant strains was noted to be zero, Fig. 1.

**Characterization of PPIs catabolization pattern among the patients**

The release of our experiment demonstrated that through the total number of patients (n = 96), there were 81.25% distinct for Homozygote extensive PPIs metabolizer with the allelic pattern of (*3/*3), 6.25% of the patients classified in Het-EM with the allelic pattern of (*2/*2) and the rest of 12.49% have been characterized for poor metabolizer category: with the allelic pattern of (*2/*2) for 10.41% and (*3/*3) for 2.08%. The pattern of (*3/*3) Het-EM was not obviously detected in our experiment.

**Cyp2c19 phenotype distribution between infected individuals**

Comparative analysis of the total number of the patients demonstrated that 63/96 histopathological examined patients and 61/96 molecular identified patients were *H. pylori* positive. Distribution of the Hom-EM (*3/*3), Het-EM (*2/*2), and PM phenotypes in infected individuals by histopathological and molecular tests reports, were ordinarily 71.42%, 9.52%, 19.04%, and 70.49%, 9.83%, and 19.66%. Poor metabolism pattern within the histopathological reported *H. pylori*-positive patients were (*2/*2)15.87%, (*3/*3) 3.17% and for molecular identified patients recorded 16.39% for (*2/*2) and 3.27% for (*3/*3).

**PPIs metabolizer phenotype patterns and profile of CAM-resistant**

In the manner of cyp2c19 gene dosage profiling between CAM-R strains that circulated through the population with the perspective of personalized therapy; replacement of the drug, duration, or drug dosing; first, 35/96 (36.45%) of the individual phenotypically evaluated *Heli-cobacter pylori* positive, that the prevalence of Hom-EM participants (*3/*3), Het-EM(*2/*2) and PM (*2/*2) vs (*3/*3) were reported 48.57%, 17.14%, 28.57% and 5.71% ordinarily. Details have already accumulated in Table 1.

In this survey, there was significant coverage between CAM-resistant strains 16/35(45.71%), and the distribution of two phenotypes of PPIs metabolism rate: 62.5% for PM (*2/*2) and 37.5% for Het-EM (*2/*2).

The more interesting notification of our results was the accumulation of the total number of the point mutations (A2143C and rpl22 GTG deletion or 9 bp insertion)
correlated with the CAM-R strains in two phenotypes: PM (*2/*2), and Het-EM(*2/*2). According to our study from (10/16) 62.5% of poor metabolizer patients were characterized for the allelic pattern of (*2/*2); spanning of CAM-R related point mutations noted to be: 1/10 for A2143C, 8/10 for rpl22 9bp insertion, and 2/10 for rpl22 GTG deletion and 9 bp insertion. The molecular pattern of the rest of 6/16 (37.5%) CAM-R isolates with rpl22 9 bp insertion, are classified in Het-EM (Table 2).

**Discussion**

According to Kyoto global consent reports the sensitive, available, rapid, and cost-effective molecular approaches are the health care needed to control the *Helicobacter pylori* related disease (prophylactic purpose), and improve the cure rate by determination of local CAM-R profile and PPIs-metabolization rate [13–15].

Indeed, this experiment was performed to evaluate the local profile of Clarithromycin resistant strains infected patients consequently *cyp2c19*1, *2, *3 patients’ pattern in PPIs (omeprazole and lansoprazole) metabolization rate.

Based on our survey, the most proportion of the patients, histopathological and molecular infected subjects, and culture-positive patients, are classified in the Hom-EM class, that the differences of *cyp2c19* *1* polymorphisms mention being statistically highly significant (P ≤ 0.001). This report is strongly supported by Mahmoudi Saber et al. [16] in Tehran, where the rate of Hom-extensive metabolizer patients was reported for 85.9%. Didevar et al. [17] by investigating the Azari Turkish healthy individuals, demonstrated the most content of the subjects categorized in the Hom-EM group. According to our work, the rest of the patients were classified as PM (12.49%) and Het-EM (6.25%). The report of statistics in *cyp2c19*2 mapping, revealed that the differences were more significant than *cyp2c19*3, p ≤ 0.75. A comprehensive review of the Iranian *cyp2c19* gene Polymorphisms Population reported the spanning of *2 variants (13.6%) that the prevalence was obviously in a row with our work [18], they have been reported *3 allelic variations with the minor allele frequent class (MAF) ≤ 1% that based on our experiment the prevalence of *3 allelic polymorphism described spanning in limited subjects 2.08% p ≤ 0.75.

The release of our clinical study illustrated that there was no significant relationship between the *cyp2c19* allelic distribution, and the age or gender of the participants, respectively.

Based on our findings, Het-EM patients allelic combination exhibited *2/*2 pattern in diagnosis, which was in order with Saber et al. [19]. In both studies, the association of Het-EM patients with the *3/*3 pattern was considered to be zero. Illustration of the dominant *2/*2 structure of PM patients in our study revealed the similarity to, Saber et al. [16], Namazi et al. [19], Zendehdel et al. [20], and whom reported the relationship between the dominant *2/*2 pattern in PM patients. However, in our experiment, small portion of

| Target gene | Mutation | PPIs metabolism Phenotype | Metabolization pattern | Total number of CAM-resistant strains |
|-------------|----------|---------------------------|------------------------|--------------------------------------|
| 23SrRNA     | A2143C transition | PM | *2/*2 | 1/16 |
| rpl22       | TTCATGTA insertion | PM | *2/*2 | 10/16 |
| rpl22       | TTCATGTA insertion | Het-EM | *2/*2 | 6/16 |
| rpl22       | GTG deletion | PM | *2/*2 | 2/16 |
PM phenotype was considered for *3/*3 pattern, and in their study, such combination was noticed to be zero.

Based on a series of studies exceeded the rate of Clarithromycin resistance up to 15%, and replacement of standard triple therapy by Bismuth quadruple therapy, hybrid (or reverse hybrid) therapy, and concomitant therapy are on the double scale in the prescription [21]. Case-to-case therapy by determination of CAM-R pattern and cyp2c19 polymorphisms improve the superior in quality, with fewer adverse events [22]. In Turkey, the consequences of CAM-R strains rose rate to 40% linked to decreases in STT efficiency of 55.7% [9]. Choi et al. [22] indicated that 23S rRNA point mutations monitoring in CAM-R strains increase the eradication rate from 82.6% to 91.2%. Nor efficiency improvement but also the rate of eradication-related side effects decreased by 12.0%, which significantly looks different from empirical bismuth quadruple therapy for H. pylori first-line eradication regime.

To pretreatment ideally therapy, these findings led us to categorize the patients based on Clarithromycin resistance and pattern of PPIs metabolization rate, and results reported to the physicians. The findings demonstrated that 100% of the phenotypically CAM-R strains are covered by rpl22 mutations. According to us all the Clarithromycin sensitive patients classified in Homozygote extensive metabolizer group, and all the CAM-resistant patients described for PM 62.5% and Het-EM 37.5%, respectively. It is worth mentioning that accumulation of all CAM-R strains increase the eradication rate from 82.6% to 91.2%. Nor efficiency improvement but also the rate of eradication-related side effects decreased by 12.0%, which significantly looks different from empirical bismuth quadruple therapy for H. pylori first-line eradication regime.

For the purpose of tailoring therapy, we introduced three groups of patients to clinicians: first, CAM-R infected subjects (Tagged for 23S rRNA and rpl22 related point mutations) for drug replacement or alternative treatment regime in use; second, PM patients in CAM-S group (that may suffer from long-term PPIs and side effects), and CAM-R groups; finally, EM patients that the risk of infection recurrence by standard PPIs dose scheduling consider to be very high. Short time for patient follows up project, online system for requesting follow-up appointments, and physician’s persistence in empirical therapy rather than per-patient therapy could be our limitations in this experiment.

Abbreviations
CAM-R: Clarithromycin resistant; PPIs: Proton pumps inhibitors; STT: Standard triple therapy; LOF: loss of functions; Hom-EM: Homozygote extensive metabolizer; Het-EM: Heterozygote extensive metabolizer; PM: Poor metabolizer; ADR: Antimicrobial drug resistance; WHO: World Health Organization; RCTs: Randomized controlled trials; MAF: Minor allele frequent.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13104-022-06227-5.

Acknowledgements
Not applicable.

Author contributions
AAM and AMM developed the idea, designed the study, AAM, AS and AY collected the samples, AAM, AMM, SE and MN analyzed the data and drafted the manuscript. AMM reviewed and revised the manuscript. All authors read and approved the final manuscript.

Funding
This study was supported by IRAN National Science Foundation (INSF) 98020892.

Availability of data and materials
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Declarations

Ethics approval and consent to participate
This survey was approved by the Ethics Committee of Tarbiat Modares University (IR-MODARES.REC.1398/019), Tehran, Iran, all the participants have accepted and signed the informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Al-E Ahmad Exp., Tehran, Iran. 2Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3Department of Nanobiotechnology, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran. 4Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical, Sciences, Tehran, Iran. 5National Reference Laboratory for Plague, Tularemia and Q Fever, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.

Received: 22 May 2022 Accepted: 14 October 2022 Published online: 25 October 2022

References
1. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008;5:321–31. https://doi.org/10.1038/ncpgasthep1138.
2. Tuan VP, Narith D, Tshibangu-Kabamba E, Dung HDQ, Viet PT, Sokomoth. et al. A next-generation sequencing-based approach to identify genetic determinants of antibiotic resistance in Cambodian Helicobacter pylori clinical isolates. J Clin Med. 2019;8:608. https://doi.org/10.3390/jcm8060680.
3. Binh TT, Shiotia S, Suzuki R, Matsuda M, Trang TTH, Kwon DH, Iwatani S, Yamaoka Y. Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing. J Antimicrob Chemother. 2014;69:1796–803. https://doi.org/10.1093/jac/dku250.
4. Miftahussurur M, Syam AF, Nusi IA, Makmun D, Waskito LA, Zein LH, Akil F, Arief DA, Sulistiyowati S, Binh TT, Sokhem S, Tri TD, Ngov S. A next-generation sequencing-based approach to identify genetic determinants of antibiotic resistance in Cambodian Helicobacter pylori clinical isolates. J Clin Med. 2019;8:608. https://doi.org/10.3390/jcm8060680.
5. Kuo C-H, Lu C-Y, Shih H-Y, Liu C-J, Wu M-C, Hu H-M, Hsu W-H, Yu F-J, Wu D-C, Kuo F-C. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J of Gastroenterol. 2016;20:629. https://doi.org/10.3748/wjg.v20i43.1629.
6. Yang J-C, Yang YF, Liao Y-S, Lin CL, Wang TH. Pharmacokinetic–pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori. Br J Clin Pharmacol. 2009;67:503–10. https://doi.org/10.1111/j.1365-2125.2009.03399.x.
7. Arevalo-Galván A, Otero-Regino WA, Ovallés-Celis GN, Rodríguez-Gómez ER, Trespalacios-Rangel AA. Prevalence of CYP2C19 polymorphism in Bogotá, Colombia: the first report of allele *17. PLoS ONE. 2021;16:e0245401. https://doi.org/10.1371/journal.pone.0245401.
8. Peng X, Song Z, He L, Lin S, Gong Y, Sun L, Zhao F, Gu Y, You Y, Zhou L. Gastric juice-based real-time PCR for tailored Helicobacter pylori treatment: a practical approach. Int J Mol Sci. 2017;18:595. https://doi.org/10.3390/ijms18091896.
9. Kaplan M, Tanoglu A, Duzenli T, Tozun AN. Helicobacter pylori treatment in Turkey: current status and rational treatment options. North Clin Istamb. 2020;7:87. https://doi.org/10.14744/nci.2020.62558.
10. Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Shirai N, Ikuma M, Hishida A, Ishizaki T. Personalized medicine for eradication of Helicobacter pylori. Per Med. 2007. https://doi.org/10.21271/17140541.4.3.321.